Penalty for Lengthy Drug Delivery Talks Will Lift Price Settlement Rates: Minister
To read the full story
REGULATORY
- MHLW Orders Label Revisions for Semaglutide, Tirzepatide to Include Ileus Risk
July 31, 2025
- 23 Suspected Promotional Violations Identified for 18 Drugs in FY2024: MHLW
July 31, 2025
- MHLW Panel to Further Review Positioning of Susmed’s Insomnia App
July 31, 2025
- MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
- MHLW Raises Drug R&D, Supply Stability as FY2026 Budget Priorities
July 30, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…